Why Did SoFi Stock Drop?
Fintech platform SoFi (NASDAQ:SOFI) has stumbled in recent days, selling…
Sell
36
CODX Quote, Financials, Valuation and Earnings
Last price:
$0.35
Seasonality move
:
5.85%
Day range:
$0.34 - $0.37
52-week range:
$0.23 - $1.55
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
25.09x
P/B ratio:
0.57x
Volume:
841.3K
Avg. volume:
42.2M
1-year change:
-59.24%
Market cap:
$22.8M
Revenue:
$770K
EPS (TTM):
-$0.96
Analysts' Opinion
-
Consensus RatingCo-Diagnostics, Inc. has received a consensus rating of Hold. The company's average rating is a Hold based on 0 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $1.50, Co-Diagnostics, Inc. has an estimated upside of 300.53% from its current price of $0.35.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $1.50 representing 100% downside risk from its current price of $0.35.
Fair Value
-
According to the consensus of 1 analyst, Co-Diagnostics, Inc. has 300.53% upside to fair value with a price target of $1.50 per share.
CODX vs. S&P 500
-
Over the past 5 trading days, Co-Diagnostics, Inc. has overperformed the S&P 500 by 0.74% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Co-Diagnostics, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Co-Diagnostics, Inc. revenues have been falling on a year-over-year basis for 1 quarter in a row. In the most recent quarter Co-Diagnostics, Inc. reported revenues of $145.4K.
Earnings Growth
-
Co-Diagnostics, Inc. has grown year-over-year earnings for 4 quarters straight. In the most recent quarter Co-Diagnostics, Inc. reported earnings per share of -$0.16.
Enterprise value:
12.8M
EV / Invested capital:
0.31x
Price / LTM sales:
25.09x
EV / EBIT:
--
EV / Revenue:
25.27x
PEG ratio (5yr expected):
-0.11x
EV / Free cash flow:
-0.40x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1M
Return On Assets:
-55.5%
Net Income Margin (TTM):
-6336.17%
Return On Equity:
-65.15%
Return On Invested Capital:
-62.71%
Operating Margin:
-4823.8%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | $4.7M | $4.2M | $507.9K | $206.9K | $145.4K | |
| Gross Profit | $1.7M | -$869K | -$1M | -$441.8K | -$148.3K | |
| Operating Income | -$41.6M | -$43.1M | -$35.5M | -$10.7M | -$7M | |
| EBITDA | -$40.4M | -$41.8M | -$34.3M | -$10.3M | -$6.7M | |
| Diluted EPS | -$1.42 | -$1.35 | -$0.96 | -$0.32 | -$0.16 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $102.3M | $101.9M | $71.3M | $40.1M | $14.1M | |
| Total Assets | $105.4M | $147.8M | $108.7M | $72.4M | $44.7M | |
| Current Liabilities | $4.1M | $6M | $5.1M | $5.8M | $3.7M | |
| Total Liabilities | $5.2M | $12.9M | $9.2M | $8.6M | $4.9M | |
| Total Equity | $100.2M | $134.9M | $99.5M | $63.8M | $39.8M | |
| Total Debt | -- | $126.3K | $2.3M | $1.5M | $727.9K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$21.3M | -$25.7M | -$31.2M | -$7.2M | -$5.9M | |
| Cash From Investing | -$47.5M | $26.4M | $26.9M | $4.2M | $2.2M | |
| Cash From Financing | -$2.4M | -$159.7K | $4.9M | -- | $4.1M | |
| Free Cash Flow | -$22.5M | -$26.8M | -$31.8M | -$7.4M | -$6M | |
CODX
Sector
Market Cap
$22.8M
$28.5M
Price % of 52-Week High
24.16%
51.44%
Dividend Yield
0%
0%
Shareholder Yield
-28.53%
-1.33%
1-Year Price Total Return
-54.33%
-20.32%
Beta (5-Year)
1.149
0.520
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.37
200-day SMA
Sell
Level
$0.35
Bollinger Bands (100)
Sell
Level
0.25 - 0.47
Chaikin Money Flow
Buy
Level
447.2M
20-day SMA
Sell
Level
$0.36
Relative Strength Index (RSI14)
Sell
Level
46.94
ADX Line
Buy
Level
42.43
Williams %R
Neutral
Level
-39.5615
50-day SMA
Sell
Level
$0.39
MACD (12, 26)
Sell
Level
-0.01
25-day Aroon Oscillator
Sell
Level
-48
On Balance Volume
Neutral
Level
1.3B
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-1.3405)
Sell
CA Score
(Annual)
Level (-1.3023)
--
Beneish M-Score
(Annual)
Level (--)
Sell
Momentum Score
Level (2)
Sell
Ohlson Score
Level (4.5814)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Buy
Fundamental Score
Level (4)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Co-Diagnostics, Inc. engages in the development and innovation of molecular tools for detection of infectious diseases, liquid biopsy for cancer screening, and agricultural applications. Its diagnostics systems enable very rapid, low-cost, molecular testing for organisms and genetic diseases by automating historically complex procedures in both the development and administration of tests. The company was founded by Brent C. Satterfield and Dwight Howard Egan on April 18, 2013 and is headquartered in Salt Lake City, UT.
Stock Forecast FAQ
In the current month, CODX has received 0 Buy ratings 1 Hold ratings, and 0 Sell ratings. The CODX average analyst price target in the past 3 months is $1.50.
-
Where Will Co-Diagnostics, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Co-Diagnostics, Inc. share price will rise to $1.50 per share over the next 12 months.
-
What Do Analysts Say About Co-Diagnostics, Inc.?
Analysts are divided on their view about Co-Diagnostics, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Co-Diagnostics, Inc. is a Sell and believe this share price will drop from its current level to $1.50.
-
What Is Co-Diagnostics, Inc.'s Price Target?
The price target for Co-Diagnostics, Inc. over the next 1-year time period is forecast to be $1.50 according to 1 Wall Street analyst, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is CODX A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Co-Diagnostics, Inc. is a Hold. 1 of 1 analysts rates the stock a Hold at this time.
-
How Can I Buy Shares Of CODX?
You can purchase shares of Co-Diagnostics, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Co-Diagnostics, Inc. shares.
-
What Is The Co-Diagnostics, Inc. Share Price Today?
Co-Diagnostics, Inc. was last trading at $0.35 per share. This represents the most recent stock quote for Co-Diagnostics, Inc.. Yesterday, Co-Diagnostics, Inc. closed at $0.35 per share.
-
How To Buy Co-Diagnostics, Inc. Stock Online?
In order to purchase Co-Diagnostics, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get CODX Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
CODX
Sector
P/E ratio
--
23.75x
PEG ratio
-0.11x
-0.01x
P/B ratio
0.57x
1.83x
Price / LTM sales
25.09x
1.60x
Growth Metrics
CODX
Sector
Revenue growth
-29.73%
4.85%
Earnings growth
51.13%
11.11%
Revenue (5-year growth)
29.07%
6.45%
Earnings forecast
-$0.19
-$0.20
Profitability
CODX
Sector
Profitability FY 2024
-$1.6M
$3.6M
Return on invested capital
-62.71%
-30.98%
Return on assets
-55.5%
-27.62%
Return on equity
-65.15%
-36.69%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Mar
31
Estimated Next Earnings Date
Feb
12
Balance Sheet
CODX
Sector
Total cash
$11.4M
$27.2M
Short term investments
$26.8M
$25.7M
Total assets
$71.2M
$79.7M
Long term debt
$727.9K
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Robinhood Win AI Investing?
Recently, online brokerage Robinhood (NASDAQ:HOOD) has been focused on introducing…
Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.4T
P/E Ratio: 62x
Buy
56
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 37x
Buy
81
Is GOOG Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 40x
Alerts
Buy
56
SMX alert for Dec 8
SMX (Security Matters) Plc [SMX] is down 59.64% over the past day.
Buy
72
KYMR alert for Dec 8
Kymera Therapeutics, Inc. [KYMR] is up 41.67% over the past day.
Buy
62
PRAX alert for Dec 8
Praxis Precision Medicines, Inc. [PRAX] is up 9.18% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
